Cleancard vs Amgen

Side-by-side comparison of AI visibility scores, market position, and capabilities

Amgen leads in AI visibility (88 vs 45)
Cleancard logo

Cleancard

EmergingHealthcare

General

US YC S23 at-home 30-minute cancer screening for prostate, bladder, and ovarian cancers; $846K Mayo Clinic/TQ Ventures/YC-backed with synthetic biology + computer vision from Oxford Rhodes Scholar founders competing with GRAIL for accessible early...

AI VisibilityBeta
Overall Score
C45
Category Rank
#326 of 596
AI Consensus
76%
Trend
stable
Per Platform
ChatGPT
50
Perplexity
42
Gemini
50

About

Cleancard is a United States-based at-home cancer screening company — backed by Y Combinator (S23) with $846,000 in total funding from Mayo Clinic Platform, TQ Ventures, Urban Innovation Fund, Y Combinator, and the Creative Destruction Lab — developing a 30-minute at-home diagnostic platform that combines synthetic biology, machine learning, and computer vision to detect multiple cancer biomarkers from a single patient sample for prostate, bladder, and ovarian cancers. Founded by Luca Springer and Thomas Carroll (both Rhodes Scholars from Oxford), Cleancard targets the massive unmet need for accessible, affordable cancer screening outside of clinical settings — the 30-minute result time and home-based format enabling screening at the frequency and convenience required for early cancer detection programs.

Full profile
Amgen logo

Amgen

LeaderHealthcare Tech

AI Drug Discovery

Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.

AI VisibilityBeta
Overall Score
A88
Category Rank
#3 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
83
Perplexity
87
Gemini
85

About

Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.

Full profile

AI Visibility Head-to-Head

45
Overall Score
88
#326
Category Rank
#3
76
AI Consensus
78
stable
Trend
stable
50
ChatGPT
83
42
Perplexity
87
50
Gemini
85
43
Claude
90
44
Grok
92

Key Details

Category
General
AI Drug Discovery
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Amgen
AI Drug Discovery

Integrations

Amgen is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.